M2GEN, a company focused on transforming cancer care through data and informatics, announced the appointment of Jim Gabriele as President and Chief Executive Officer. Gabriele is a seasoned entrepreneur and data science leader who most recently served as Senior Vice President and Chief Strategy & Data Science Officer, Medical Devices Sector, at Johnson & Johnson.
Gabriele was selected to lead M2GEN based on his track record of leading growth initiatives and digital transformations, deep understanding of biopharma, and capability-building skills in key technology and data analytics that are critical priorities for M2GEN.
M2GEN has established one of the largest and most comprehensive linked clinical and genomic databases in the country, empowering innovative, collaborative cancer research and supporting the development of novel oncology drugs by its biopharmaceutical partners. M2GEN runs one of the world’s largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease.
Also Read: Top 10 Tech Trends In The Middle East
Gabriele has more than 30 years of experience as a senior executive at leading pharmaceutical, medical device and consulting organisations. Most recently, at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights. Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organisation.
Previously, Gabriele built and served as Managing Director and Operating Partner for Henry Rak Consulting Partners, a successful strategy and analytics company serving large global Pharmaceutical, Medical Device and CPG companies. It was acquired by McKinsey & Company and later renamed HRC. Gabriele received a BA in Economics & Government from the College of William & Mary and an MBA from Harvard Business School. He serves on the advisory board of Finpay Holdings.
